Headache

Merck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9

Retrieved on: 
Wednesday, March 13, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, MSD, Hypersensitivity, Pregnancy, Wart, Head, Congress, Recombinant, Multiple endocrine neoplasia, Dizziness, Safety, Vain, Headache, Bruise, Public, Syncope, Ageing, Merck & Co., Cervical intraepithelial neoplasia, Vulvar intraepithelial neoplasia, Anal cancer, Virus-like particle, Observation, CIN, Thigh, Human, HPV, Plant, Vaginal intraepithelial neoplasia, Nausea, MRK, VLP, Investment, Immunity, Fever, Erythema, Vaccination, Injury, Vaccine, Allergy, Itch, AIN, Swelling

Separately, the company also plans to conduct clinical trials in both females and males to evaluate the efficacy and safety of a single-dose regimen of GARDASIL®9 (Human Papillomavirus 9-valent, recombinant), compared to the approved three-dose regimen.

Key Points: 
  • Separately, the company also plans to conduct clinical trials in both females and males to evaluate the efficacy and safety of a single-dose regimen of GARDASIL®9 (Human Papillomavirus 9-valent, recombinant), compared to the approved three-dose regimen.
  • Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
  • The latest addition to the pipeline employs the company’s proprietary virus-like particle (VLP) technology to incorporate additional VLPs for expanded HPV type coverage.
  • These randomized, double-blind, multi-year clinical trials will examine the short and long-term efficacy and immunogenicity of a single-dose of GARDASIL 9 versus the currently approved three-dose regimen.

Azul Reports Accelerated Growth Across Product Lines and Geographies, Boosted by Oracle’s Java Pricing Change and Rising Cloud Costs

Retrieved on: 
Tuesday, March 12, 2024
Data Management, Technology, Mobile, Wireless, Software, Networks, Internet, Cloud, Graviton, Consultant, Uncertainty, University of Sydney, ARR, Growth, University, Headache, Policy, ARM, AWS, Java Platform, Standard Edition, Cisco, Investment, Crac, Oracle, AWS Graviton, Intelligence, Cloud computing, Core, OpenJDK, Video game

Azul , the only company 100% focused on Java, today announced accelerated growth last year across its product portfolio and geographies, including unprecedented demand for its OpenJDK products in the wake of Oracle’s Java SE pricing policy change and enterprises grappling with soaring cloud costs.

Key Points: 
  • Azul , the only company 100% focused on Java, today announced accelerated growth last year across its product portfolio and geographies, including unprecedented demand for its OpenJDK products in the wake of Oracle’s Java SE pricing policy change and enterprises grappling with soaring cloud costs.
  • Since that announcement, Azul has seen tremendous growth in new customer bookings for its OpenJDK-based Oracle alternative, Azul Platform Core , with an increase of 49% year-over-year.
  • One customer, the University of Sydney, switched from Oracle Java to Azul Platform Core, looking for cost savings, greater predictability and ease of doing business.
  • Reinforcing its leadership in Java, Azul was also re-elected to the Java Committee Executive Team, a key steering committee for Java, its development and roadmap.

Windstream Enterprise Debuts Secure Flex Premium with Fortinet for Maximum Enterprise Agility and Digital Acceleration

Retrieved on: 
Monday, March 11, 2024
Telecommunications, Software, Networks, Internet, Data Management, Technology, Mobile, Wireless, Security, ZTNA, Headache, Environment, EPP, Health, Windstream Holdings, Risk, Seamless, Secure access service edge, CISO, Policy, AI, Ecosystem, Posture, Risk management

What’s more, these larger businesses are struggling to stitch together disparate point solutions, which leads to increased complexity and vulnerability within an enterprise’s digital environment.

Key Points: 
  • What’s more, these larger businesses are struggling to stitch together disparate point solutions, which leads to increased complexity and vulnerability within an enterprise’s digital environment.
  • Delivered by Windstream Enterprise’s IT Managed Services team, Secure Flex Premium leverages Fortinet’s unique AI-powered cybersecurity platform, the Fortinet Security Fabric, and Fortinet’s secure networking solutions to enable clients to meet these business-critical demands, accelerate digital transformation initiatives, and provide complete visibility and control into their unique IT landscape.
  • Dedicated single-tenant solution: Secure Flex Premium is designed exclusively for each client to ensure a higher degree of control and customization over their entire IT environment.
  • With Windstream Enterprise as the managed services provider, enterprises remove the challenges and risk of managing disjointed point solutions from multiple vendors.

Lindus Health Partners with Amendola for PR Program to Promote Groundbreaking Model that Streamlines End-to-End Clinical Trials for Life Sciences

Retrieved on: 
Thursday, April 4, 2024
ChromeOS, Research, Headache, Running, AI

Amendola is implementing a comprehensive PR plan to demonstrate Lindus Health's industry-leading technology and services, accomplishments, customer wins, and industry partnerships.

Key Points: 
  • Amendola is implementing a comprehensive PR plan to demonstrate Lindus Health's industry-leading technology and services, accomplishments, customer wins, and industry partnerships.
  • "We are thrilled to work with Amendola to demonstrate to the market how Lindus Health's new model offers more rapid, high-quality clinical trials together with transparent pricing."
  • The company is passionate about using the highest-quality scientific methods available and homegrown cutting-edge technology, including AI, to conduct radically faster, more reliable clinical trials.
  • "Lindus Health is poised to transform how clinical trials are executed and we look forward to raising awareness across the industry."

NURTEC ODT® is Now Available in Canada for the Treatment of Acute Migraine

Retrieved on: 
Thursday, April 4, 2024
Neurology, University, Vii, Disability, Sound, Pfizer, CGRP, Headache, Migraine, Ageing, Light, Health Canada, Nausea, Myenteric plexus

KIRKLAND, QC, April 4, 2024 /CNW/ - NURTEC ODT® (rimegepant) is now available in Canada for use in the acute treatment of migraine, with or without aura in adults older than 18 years of age.iii NURTEC is an orally disintegrating calcitonin gene-related peptide (CGRP) receptor antagonist tablet.

Key Points: 
  • KIRKLAND, QC, April 4, 2024 /CNW/ - NURTEC ODT® (rimegepant) is now available in Canada for use in the acute treatment of migraine, with or without aura in adults older than 18 years of age.iii NURTEC is an orally disintegrating calcitonin gene-related peptide (CGRP) receptor antagonist tablet.
  • "It is an exciting time for Canadians to now have another targeted, migraine specific therapy in their management toolbox."
  • People living with migraine are looking for timely and equitable access to new options to effectively manage this highly debilitating disease," said Wendy Gerhart from Migraine Canada.
  • "Pfizer Canada is proud to bring this new therapy to Canadians impacted by migraine," said Andréa Mueller, Primary Care Portfolio Lead, Pfizer Canada.

FDA Approves New Antibiotic for Three Different Uses

Retrieved on: 
Wednesday, April 3, 2024
Daptomycin, Research, Hypersensitivity, Hypokalemia, Fungal infection, Aztreonam, Dizziness, Pneumonia, Survival, Dysgeusia, Potassium, Seizure, Abdominal pain, Dietary supplement, CABP, Headache, Patient, Public, Insomnia, Bacterial pneumonia, Food and Drug Administration, Animal, Bilirubin, Diarrhea, History, Mortality, Vancomycin, Leukopenia, Clostridioides, Human services, Injection site reaction, Nausea, Rash, Priority review, Bronchopneumonia, Skin, Fever, Heated tobacco product, Ceftriaxone, Safety, SAB, Anemia, Division, Phlebitis, Cosmetics, Vaccine, Infection, Food, Vomiting, Blood, Multimedia, FDA, Periodic breathing, ABSSSI, Pharmaceutical industry

"The FDA will continue our important work in this area as part of our efforts to protect the public health."

Key Points: 
  • "The FDA will continue our important work in this area as part of our efforts to protect the public health."
  • Zevtera's efficacy in treating SAB was evaluated in a randomized, controlled, double-blind, multinational, multicenter trial .
  • In the trial, researchers randomly assigned 390 subjects to receive Zevtera (192 subjects) or daptomycin plus optional aztreonam [the comparator] (198 subjects).
  • A total of 69.8% of subjects who received Zevtera achieved overall success compared to 68.7% of subjects who received the comparator.

China has committed to boosting foreign investors' confidence and a sense of belonging

Retrieved on: 
Wednesday, April 3, 2024
Spouse, Eye, Law enforcement, Headache, Policy, Jing'an Temple, Renewable energy

Like Cook said, "there's no supply chain in the world that's more critical to us than China."

Key Points: 
  • Like Cook said, "there's no supply chain in the world that's more critical to us than China."
  • More foreign entrepreneurs have been visiting China lately, showing high spirits about investing in the country.
  • A reason behind the tide is that China has stepped up efforts in opening its doors wider and attracting and utilizing foreign investment.
  • China has committed itself to enhancing the confidence and the sense of belonging of foreign investors in China.

Hamline University Research Validates Highly Cost-Effective Impairment Assessment Algorithm for Workers' Compensation Cases

Retrieved on: 
Wednesday, April 3, 2024
Physics, NP-hardness, Health, American Medical Association, Headache, Patient, FLR, Research, Table, Doctor of Philosophy, MD, Insurance, ADL, Lawyer, FCR, Heart, WPI, QME, Fifth Edition, Hamline University, Nursing

ST. PAUL, Minn., April 3, 2024 /PRNewswire-PRWeb/ -- Hamline University, in collaboration with impairment rating calculations company Rate-Fast, today announced groundbreaking research that revolutionizes the assessment of impairment in workers' compensation cases. The study validates a novel algorithm-based Functional Loss Rating (FLR) method, which offers a more objective, efficient, and cost-effective approach for calculating a whole-person impairment (WPI) score, upon which compensation for work-related injuries is based. The study demonstrates that the computational FLR method is consistently more accurate than the traditional, manual Four Corners Rating (FCR) system, the current industry standard for WPI measurement.

Key Points: 
  • ST. PAUL, Minn., April 3, 2024 /PRNewswire-PRWeb/ -- Hamline University, in collaboration with impairment rating calculations company Rate-Fast, today announced groundbreaking research that revolutionizes the assessment of impairment in workers' compensation cases.
  • The study validates a novel algorithm-based Functional Loss Rating (FLR) method, which offers a more objective, efficient, and cost-effective approach for calculating a whole-person impairment (WPI) score, upon which compensation for work-related injuries is based.
  • FLR is a mathematical impairment evaluation method that uses advanced data analytics to calculate an objective, accurate WPI rating.
  • The algorithm at the heart of FLR was built on more than a decade of research comprised of nearly 70,000 impairment case rating experiences.

HeadaTerm 2: The Most Affordable FDA Cleared Innovative OTC Anti-Migraine Device

Retrieved on: 
Tuesday, April 2, 2024
Annals of Emergency Medicine, Veteran, Headache (journal), Headache, Patient, American Journal, Emergency medicine, McMaster University, University, Software, Migraine, OTC, Ohio State University, Multimedia, University of Toronto, FDA, Food, Medical device

Using neuromodulation technology, HeadaTerm 2 releases targeted electrical impulses to increase pain tolerance of its users.

Key Points: 
  • Using neuromodulation technology, HeadaTerm 2 releases targeted electrical impulses to increase pain tolerance of its users.
  • HeadaTerm 2 is a testament of WAT Medical's continued commitment to providing safe, effective, and user-friendly innovative medical devices at the most competitive price.
  • It provided an affordable solution to a debilitating condition that affects nearly 40 million people in the U.S. HeadaTerm 2 is a rechargeable device that features adjustable intensity setting and will be the most affordable device of its kind.
  • HeadaTerm 2 will appear at the 66th Annual Scientific Meeting in June 2024 hosted by American Headache Society.

Spence Law Firm LLC: Family Alleges Gas Poisoning in Airbnb Vacation Home

Retrieved on: 
Monday, April 1, 2024
Headache, Poisoning, Risk, District court, SAN, Smell, Brain, Child, Infant, Carbon, Nausea, Vomiting, MediaWorks, Family, Carbon monoxide

SAN FRANCISCO and SANTA FE, N.M., April 1, 2024 /PRNewswire/ -- A Montana family of four alleges in new lawsuits that they were poisoned by a boiler spewing carbon monoxide gas into an Airbnb vacation rental home in Santa Fe, N.M., The Spence Law Firm and co-counsel said today.

Key Points: 
  • SAN FRANCISCO and SANTA FE, N.M., April 1, 2024 /PRNewswire/ -- A Montana family of four alleges in new lawsuits that they were poisoned by a boiler spewing carbon monoxide gas into an Airbnb vacation rental home in Santa Fe, N.M., The Spence Law Firm and co-counsel said today.
  • Tyson E. Logan , of The Spence Law Firm, said, "This is an urgent issue.
  • The poisoning did permanent and irreversible damage to this family, especially the youngest child – it will affect them forever.
  • Contact: Erin Powers, Powers MediaWorks LLC, for The Spence Law Firm, LLC, 281.703.6000, [email protected] .